Intellect Neurosciences, Inc. Adds Two New Patent Allowances to Its Global Patent Portfolio
8/1/2012 9:05:06 AM
NEW YORK, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the European Patent Office (EPO) for OX1, which has been licensed to ViroPharma for Friedrich's Ataxia and other neurodegenerative diseases. Separately, the company received a similar notice from the Israeli patent office for the RECALL-VAX platform technology that underlies RV03, its first-in-class bi-specific vaccine targeting beta amyloid and delta tau for the treatment and prevention of Alzheimer's disease.